As AstraZeneca closes in on developing a vaccine against COVID-19, the U.K. pharma giant struck a deal with Europe’s Inclusive Vaccines Alliance to supply up to 400 million doses of the preventative medication by the end of 2020.

AstraZeneca Plc signed a contract with European governments to supply the region with a potential vaccine against the coronavirus, the British drugmaker’s latest deal to pledge the company’s drug to help combat the pandemic.